Intraperitoneal administration of cisplatin plus bevacizumab for the management of malignant ascites in ovarian epithelial cancer: results of a phase III clinical trial

Medical Oncology

Volumn 32, Issue 2, 2015, Pages 1-7

  Zhao, Hui ^a   Li, Xiaosong ^a   Chen, Dianjun ^a   Cai, Jianhua ^a   Fu, Yan ^a   Kang, Huanrong ^a   Gao, Jie ^a   Gao, Ke ^a   Du, Nan ^a  

^a CHINESE PLA GENERAL HOSPITAL   (China)

Author keywords

Bevacizumab; Intraperitoneal administration; Malignant ascites; Ovarian epithelial cancer; Overall response rate; Quality of life

Indexed keywords

BEVACIZUMAB; CA 125 ANTIGEN; CARBOPLATIN; CISPLATIN; HEMOGLOBIN; PACLITAXEL; VASCULOTROPIN; ANTINEOPLASTIC AGENT; MONOCLONAL ANTIBODY; VASCULOTROPIN A; VEGFA PROTEIN, HUMAN;

ABDOMINAL DRAINAGE; ADULT; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER PATIENT; CONTROLLED STUDY; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; ENZYME LINKED IMMUNOSORBENT ASSAY; FATIGUE; FEMALE; FEVER; HEMOGLOBIN BLOOD LEVEL; HUMAN; KARNOFSKY PERFORMANCE STATUS; LEUKOPENIA; LIVER FUNCTION; MAJOR CLINICAL STUDY; MALIGNANT ASCITES; NAUSEA AND VOMITING; NEUTROPHIL; OUTCOME ASSESSMENT; OVARY CANCER; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; PROTEIN EXPRESSION; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; THROMBOCYTOPENIA; TREATMENT RESPONSE; AGED; ASCITES; CLINICAL TRIAL; COMPLICATION; INTRAPERITONEAL DRUG ADMINISTRATION; MIDDLE AGED; NEOPLASMS, GLANDULAR AND EPITHELIAL; OVARIAN NEOPLASMS;

AGED; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; ASCITES; CA-125 ANTIGEN; CISPLATIN; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMANS; INJECTIONS, INTRAPERITONEAL; MIDDLE AGED; NEOPLASMS, GLANDULAR AND EPITHELIAL; OVARIAN NEOPLASMS; QUALITY OF LIFE; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 84921895263     PISSN: 13570560     EISSN: 1559131X     Source Type: Journal    
DOI: 10.1007/s12032-014-0292-1     Document Type: Article

References (32)

1. Rosenberg SM. Palliation of malignant ascites. Gastroenterol Clin N Am. 2006;35(1):189–99.
2. Berek JS, Hacker NF, Lagasse LD, et al. Survival of patients following secondary cytoreductive surgery in ovarian cancer. Obstet Gynecol. 1983;61(2):189–93.
3. Parsons SL, Lang MW, Steele RJ. Malignant ascites: a 2-year review from a teaching hospital. Eur J Surg Oncol. 1996;22(3):237–9.
4. Nagy JA, Herzberg KT, Masse EM, et al. Exchange of macromolecules between plasma and peritoneal cavity in ascites tumor-bearing, normal, and serotonin-injected mice. Cancer Res. 1989;49(19):5448–58.
5. Nagy JA, Herzberg KT, Dvorak JM, Dvorak HF. Pathogenesis of malignant ascites formation: initiating events that lead to fluid accumulation. Cancer Res. 1993;53(11):2631–43.
6. Yeo KT, Wang HH, Nagy JA, et al. Vascular permeability factor (vascular endothelial growth factor) in guinea pig and human tumor and inflammatory effusions. Cancer Res. 1993;53(12):2912–8.
7. Luo JC, Yamaguchi S, Shinkai A, et al. Significant expression of vascular endothelial growth factor/vascular permeability factor in mouse ascites tumors. Cancer Res. 1998;58(12):2652–60.
8. Luo JC, Toyoda M, Shibuya M. Differential inhibition of fluid accumulation and tumor growth in two mouse ascites tumors by an antivascular endothelial growth factor/permeability factor neutralizing antibody. Cancer Res. 1998;58(12):2594–600.
9. Shibuya M, Luo JC, Toyoda M, Yamaguchi S. Involvement of VEGF and its receptors in ascites tumor formation. Cancer Chemother Pharmacol. 1999;43(Suppl):S72–7.
10. Liu CD, Tilch L, Kwan D, McFadden DW. Vascular endothelial growth factor is increased in ascites from metastatic pancreatic cancer. J Surg Res. 2002;102(1):31–4.
11. Nagy JA, Masse EM, Herzberg KT, et al. Pathogenesis of ascites tumor growth: vascular permeability factor, vascular hyperpermeability, and ascites fluid accumulation. Cancer Res. 1995;55(2):360–8.
12. Shibuya M. Role of VEGF-flt receptor system in normal and tumor angiogenesis. Adv Cancer Res. 1995;67:281–316.
13. Dvorak HF, Sioussat TM, Brown LF, et al. Distribution of vascular permeability factor (vascular endothelial growth factor) in tumors: concentration in tumor blood vessels. J Exp Med. 1991;174(5):1275–8.
14. Senger DR, Galli SJ, Dvorak AM, et al. Tumor cells secrete a vascular permeability factor that promotes accumulation of ascites fluid. Science. 1983;219(4587):983–5.
15. Kanayama H, Yano S, Kim SJ, et al. Expression of vascular endothelial growth factor by human renal cancer cells enhances angiogenesis of primary tumors and production of ascites but not metastasis to the lungs in nude mice. Clin Exp Metastasis. 1999;17(10):831–40.
16. Byrne AT, Ross L, Holash J, et al. Vascular endothelial growth factor-trap decreases tumor burden, inhibits ascites, and causes dramatic vascular remodeling in an ovarian cancer model. Clin Cancer Res. 2003;9(15):5721–8.
17. Manenti L, Riccardi E, Marchini S, et al. Circulating plasma vascular endothelial growth factor in mice bearing human ovarian carcinoma xenograft correlates with tumor progression and response to therapy. Mol Cancer Ther. 2005;4(5):715–25.
18. Zhang L, Yang N, Garcia JR, et al. Generation of a syngeneic mouse model to study the effects of vascular endothelial growth factor in ovarian carcinoma. Am J Pathol. 2002;161(6):2295–309.
19. Akutagawa N, Nishikawa A, Iwasaki M, et al. Expression of vascular endothelial growth factor and E-cadherin in human ovarian cancer: association with ascites fluid accumulation and peritoneal dissemination in mouse ascites model. Jpn J Cancer Res. 2002;93(6):644–51.
20. Yano S, Shinohara H, Herbst RS, et al. Production of experimental malignant pleural effusions is dependent on invasion of the pleura and expression of vascular endothelial growth factor/vascular permeability factor by human lung cancer cells. Am J Pathol. 2000;157(6):1893–903.
21. Presta LG, Chen H, O’Connor SJ, et al. Humanization of an anti-vascular endothelial growth factor monoclonal antibody for the therapy of solid tumors and other disorders. Cancer Res. 1997;57(20):4593–9.
22. El-Shami K, Elsaid A, El-Kerm A. Open-label safety and efficacy pilot trial of intraperitoneal bevacizumab as palliative treatment in refractory malignant ascites. J Clin Oncol. 2007;25:9043 (ASCO Meeting Abstracts).
23. Hamilton CA, Maxwell GL, Chernofsky MR, et al. Intraperitoneal bevacizumab for the palliation of malignant ascites in refractory ovarian cancer. Gynecol Oncol. 2008;111(3):530–2.
24. Tamsma JT, Keizer HJ, Meinders AE. Pathogenesis of malignant ascites: starling’s law of capillary hemodynamics revisited. Ann Oncol. 2001;12(10):1353–7.
25. Schweigert FJ, Raila J, Sehouli J, Buscher U. Accumulation of selected carotenoids, alpha-tocopherol and retinol in human ovarian carcinoma ascitic fluid. Ann Nutr Metab. 2004;48(4):241–5.
26. Stuart GC, Nation JG, Snider DD, Thunberg P. Intraperitoneal interferon in the management of malignant ascites. Cancer. 1993;71(6):2027–30.
27. Adam RA, Adam YG. Malignant ascites: past, present, and future. J Am Coll Surg. 2004;198(6):999–1011.
28. Smith EM, Jayson GC. The current and future management of malignant ascites. Clin Oncol (R Coll Radiol). 2003;15(2):59–72.
29. Pichelmayer O, Gruenberger B, Zielinski C, Raderer M. Bevacizumab is active in malignant effusion. Ann Oncol. 2006;17(12):1853.
30. Pichelmayer O, Zielinski C, Raderer M. Response of a nonmalignant pleural effusion to bevacizumab. N Engl J Med. 2005;353(7):740–1.
31. Numnum TM, Rocconi RP, Whitworth J, Barnes MN. The use of bevacizumab to palliate symptomatic ascites in patients with refractory ovarian carcinoma. Gynecol Oncol. 2006;102(3):425–8.
32. Bellati F, Napoletano C, Ruscito I, et al. Complete remission of ovarian cancer induced intractable malignant ascites with intraperitoneal bevacizumab. Immunological observations and a literature review. Investig New Drugs. 2010;28(6):887–94.